162 related articles for article (PubMed ID: 37409226)
1. Azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial.
Allam MM; El-Zawawy HT; Kader Okda AA; Ali Alshaikh A; Ghazy RM
Front Endocrinol (Lausanne); 2023; 14():1168936. PubMed ID: 37409226
[TBL] [Abstract][Full Text] [Related]
2. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.
García-Mayor RV; Páramo C; Luna Cano R; Pérez Mendez LF; Galofré JC; Andrade A
J Endocrinol Invest; 1992 Dec; 15(11):815-20. PubMed ID: 1283984
[TBL] [Abstract][Full Text] [Related]
3. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.
Grebe SK; Feek CM; Ford HC; Fagerström JN; Cordwell DP; Delahunt JW; Toomath RJ
Clin Endocrinol (Oxf); 1998 May; 48(5):585-92. PubMed ID: 9666870
[TBL] [Abstract][Full Text] [Related]
6. GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES DISEASE.
Magri F; Zerbini F; Gaiti M; Capelli V; Ragni A; Rotondi M; Chiovato L
Endocr Pract; 2016 Nov; 22(11):1336-1342. PubMed ID: 27540885
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.
Abbara A; Clarke SA; Brewster R; Simonnard A; Eng PC; Phylactou M; Papadopoulou D; Izzi-Engbeaya C; Sam AH; Wernig F; Jonauskyte E; Comninos AN; Meeran K; Kelsey TW; Dhillo WS
Front Endocrinol (Lausanne); 2020; 11():286. PubMed ID: 32477269
[No Abstract] [Full Text] [Related]
8. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves' disease: a cross-sectional study.
Katahira M; Tsunekawa T; Mizoguchi A; Yamaguchi M; Tsuru K; Takashima H; Terada R
Hormones (Athens); 2023 Jun; 22(2):253-261. PubMed ID: 36811756
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
11. TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates.
Pujol P; Osman A; Grabar S; Daurès JP; Galtier-Dereure F; Boegner C; Baldet L; Raye R; Bringer J; Jaffiol C
Clin Endocrinol (Oxf); 1998 May; 48(5):635-40. PubMed ID: 9666876
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
13. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
[TBL] [Abstract][Full Text] [Related]
14. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucocorticoid pulse therapy on thyroid function and thyroid antibodies in children with graves' disease.
Hu Y; Man Y; Sun X; Xue Y
Ital J Pediatr; 2021 Mar; 47(1):46. PubMed ID: 33653401
[TBL] [Abstract][Full Text] [Related]
16. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
17. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
18. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
[TBL] [Abstract][Full Text] [Related]
19. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
